{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:21:06Z","timestamp":1740144066345,"version":"3.37.3"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["R01HS025984"],"award-info":[{"award-number":["R01HS025984"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s40264-022-01239-3","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T12:05:28Z","timestamp":1665576328000},"page":"1553-1555","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Authors\u2019 Response to Yoshihiro Noguchi\u2019s Comment on: \u201cA Disproportionality Analysis of Drug-Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS)\u201d"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5006-9394","authenticated-orcid":false,"given":"Daniel C.","family":"Malone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Villa-Zapata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ainhoa","family":"G\u00f3mez-Lumbreras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Horn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malinda S.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard D.","family":"Boyce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,12]]},"reference":[{"key":"1239_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-022-01240-w","author":"Y Noguchi","year":"2022","unstructured":"Noguchi Y. Comment on: A Disproportionality Analysis of Drug-Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS). Drug Saf. 2022. https:\/\/doi.org\/10.1007\/s40264-022-01240-w","journal-title":"Drug Saf"},{"key":"1239_CR2","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s40264-022-01200-4","volume":"45","author":"L Villa-Zapata","year":"2022","unstructured":"Villa-Zapata L, G\u00f3mez-Lumbreras A, Horn J, et al. A Disproportionality analysis of drug-drug interactions of tizanidine and CYP1A2 inhibitors from the fda adverse event reporting system (FAERS). Drug Saf. 2022;45:863\u201371.","journal-title":"Drug Saf"},{"key":"1239_CR3","unstructured":"FDA label. ZANAFLEX Capsules\u00ae (tizanidine hydrochloride). 2013. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/021447s011_020397s026lbl.pdf. Accessed 31 Aug 2022."},{"key":"1239_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s00228-020-02981-2","volume":"77","author":"A Rudolph","year":"2021","unstructured":"Rudolph A, Dahmke H, Kupferschmidt H, et al. Coadministration of tizanidine and ciprofloxacin: a retrospective analysis of the WHO pharmacovigilance database. Eur J Clin Pharmcol. 2021;77:6\u201313.","journal-title":"Eur J Clin Pharmcol."},{"key":"1239_CR5","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/cpt.1233","volume":"105","author":"S Chaugai","year":"2019","unstructured":"Chaugai S, Dickson AL, Shuey MM, et al. Co-prescription of strong CYP1A2 inhibitors and the risk of tizanidine-associated hypotension: a retrospective cohort study. Clin Pharmacol Ther. 2019;105:703\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"1239_CR6","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/1060028018775914","volume":"52","author":"AM J\u00f6dicke","year":"2018","unstructured":"J\u00f6dicke AM, Curkovic I, Zellweger U, et al. Analysis of drug-drug interactions in swiss claims data using tizanidine and ciprofloxacin as a prototypical contraindicated combination. Ann Pharmacother. 2018;52:983\u201391.","journal-title":"Ann Pharmacother"},{"key":"1239_CR7","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000029387","volume":"101","author":"HR Kim","year":"2022","unstructured":"Kim HR, Sung M, Park JA, et al. Analyzing adverse drug reaction using statistical and machine learning methods: a systematic review. Medicine. 2022;101: e29387.","journal-title":"Medicine"},{"key":"1239_CR8","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1002\/sim.3247","volume":"27","author":"GN Nor\u00e9n","year":"2008","unstructured":"Nor\u00e9n GN, Sundberg R, Bate A, et al. A statistical methodology for drug\u2013drug interaction surveillance. Stat Med. 2008;27:3057\u201370.","journal-title":"Stat Med"},{"key":"1239_CR9","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s40264-020-00939-y","volume":"43","author":"S Hult","year":"2020","unstructured":"Hult S, Sartori D, Bergvall T, et al. A feasibility study of drug-drug interaction signal detection in regular pharmacovigilance. Drug Saf. 2020;43:775\u201385.","journal-title":"Drug Saf"},{"key":"1239_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0962280211403604","volume":"22","author":"GN Nor\u00e9n","year":"2013","unstructured":"Nor\u00e9n GN, Hopstadius J, Bate A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res. 2013;22:57\u201369.","journal-title":"Stat Methods Med Res"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-022-01239-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-022-01239-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-022-01239-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T22:13:30Z","timestamp":1669414410000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-022-01239-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,12]]},"references-count":10,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1239"],"URL":"https:\/\/doi.org\/10.1007\/s40264-022-01239-3","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"type":"print","value":"0114-5916"},{"type":"electronic","value":"1179-1942"}],"subject":[],"published":{"date-parts":[[2022,10,12]]},"assertion":[{"value":"5 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was funded by the Agency for Healthcare Research and Quality, grant number R01HS025984.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/Competing interests"}},{"value":"Ethics approval from the IRB was not sought as the study only involved the analysis of data obtained from a public database. Informed consent to participate was not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"FAERS data is publicly available at:","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material (data transparency)"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability (software application or custom code)"}},{"value":"All authors contributed to the preparation of the letter and read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' contributions"}}]}}